

ARTICLE

Open Access

Pir2/Rnf144b is a potential endometrial cancer biomarker that promotes cell proliferation

Qing Zhou¹, Sahar Eldakhkhny¹, Franco Conforti², Emma J. Crosbie¹, Gerry Melino^{3,4} and Berna S. Sayan¹ 

Abstract

Endometrial cancer is one of the most common gynaecological cancers in developed countries. Its incidence has increased 20% over the last decade and the death rate has increased >100% over the past two decades. Current models for prediction of prognosis and treatment response are suboptimal, and as such biomarkers to support clinical decision-making and contribute to individualised treatment are needed. In this study, we show that the E3-ubiquitin ligase PIR2/RNF144B is a potential targetable biomarker in endometrial cancer. At transcript level, it is expressed both in normal endometrium and tumour samples, but at protein level, it is expressed in tumours only. By using endometrial cancer cell lines, we demonstrated that PIR2/RNF144B is stabilised via phosphorylation downstream of GSK3 β and this is necessary for the proliferation of endometrial cancer cells, in the absence of oestrogenic growth stimuli. Here, inactivation of GSK3 β activity is associated with loss of PIR2/RNF144B protein and consequent inhibition of cell proliferation. Our results, therefore, substantiate PIR2/RNF144B as a novel candidate for targeted therapy in endometrial cancer.

Introduction

Endometrial cancer (EC) is one of the most common gynaecological cancers worldwide and its incidence has risen by more than 50% over the last 2 decades^{1,2}. Although most women diagnosed with EC present with early-stage disease confined to the uterus, metastatic disease is identified in around 25% when comprehensive staging is performed. The 5-year overall survival for these women is extremely poor at around 20–26%^{3,4}. Current treatment for advanced EC is limited to surgery followed by chemotherapy and radiotherapy, with very few novel targeted therapies under evaluation. A better understanding of EC is urgently needed to develop novel,

efficient and effective treatment regimens, particularly for those that have spread or recurred.

EC is broadly divided into 2 types based on clinicopathological and molecular characteristics^{5,6}. Type I ECs, which account for ~80% of all cases, are driven by excessive stimulation of the endometrium by oestrogens synthesised in the fat tissue of obese women^{7–9}. Type II ECs, on the other hand, are frequently associated with p53 and p16 mutations and are oestrogen/oestrogen receptor (ER)-independent^{10,11}.

ER status in Type I EC is an important prognostic factor and higher level of ER α predicts favourable survival^{12–14}. While low-grade Type I tumours are strongly positive for ER, its expression is lost in higher-grade tumours^{15,16}. Phosphatase and tensin homolog (PTEN) mutations are also common in Type I ECs, >80% of tumours harbouring mutations targeting this pathway^{5,17}. PTEN functions as a lipid and protein phosphatase, inhibiting the ability of PDK1 to activate AKT. Loss of PTEN function results in constitutive AKT activation and phosphorylation of

Correspondence: Berna S. Sayan (berna.sayan@manchester.ac.uk)

¹University of Manchester, Faculty of Medical and Human Sciences, Division of Cancer Sciences, Manchester Cancer Research Centre, Wilmslow Road, Manchester M20 4QL, UK

²University of Southampton, Faculty of Medicine, Academic Unit of Clinical and Experimental Sciences, Southampton SO16 6YD, UK

Full list of author information is available at the end of the article

Edited by G. Raschella

© The Author(s) 2018



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

downstream targets, and hence promoting proliferation^{18–20}.

The serine/threonine kinase GSK3 β is amongst the targets of AKT. In normal uterine epithelial cells, AKT-GSK3 β signalling pathway is regulated by the actions of oestrogen and progesterone to regulate the sub-cellular localisation of cyclin D1, and hence proliferation²¹. Here, activation of AKT downstream of ER inhibits GSK3 β , which is essential for cell cycle progression²¹. As such, inhibition of GSK3 β activity induces uterine epithelial cell proliferation in human endometrial tissue xenografts²² and in parallel to this observation, it has been reported that women who had been treated with mood stabilizers, such as the GSK3 β inhibitor lithium chloride, display higher incidence of endometrial hyperplasia²³. Conversely, in EC, inhibition of GSK3 β activity is associated with inhibition of cell proliferation both *in vitro*²⁴ and *in vivo*²⁵ and GSK3 β has been shown to be overexpressed in EC, which is positively related to the stage of cancer and negatively related to relapse-free survival rate^{25,26}. These interesting observations warrant further research to understand the contradictory function of GSK3 β in endometrial tissue.

PIR2/RNF144B (hereafter referred as to PIR2) is an E3-ubiquitin ligase that is important for the regulation of apoptosis and cell proliferation^{27–29}. It is highly expressed at the basal layer of the epidermis and in head and neck squamous carcinoma (HNSCC) cells, where it regulates proliferation and differentiation²⁹. Its oncogenic role has also recently been shown in chordoma, where its depletion results in impaired cell proliferation³⁰. Here we show that PIR2 protein is not expressed in normal endometrium, but expressed only in EC. In EC cell lines, PIR2 drives cell proliferation when oestrogen-mediated growth signalling is lost. By *in silico* analysis, mass spectrometry and kinase library screening, we identified that PIR2 is phosphorylated downstream of GSK3 β and phosphorylated PIR2 is protected from proteasomal degradation, leading to its accumulation. Our findings suggest that PIR2 can potentially be used as a biomarker for endometrial cancer and inhibition of its expression may offer novel therapeutic approaches for the treatment of the disease.

Results

PIR2 is a potential endometrial cancer biomarker that drives proliferation


On the basis of the role of PIR2 in the regulation of proliferation and apoptosis, we investigated its expression profile in a panel of cell lines and identified that it is expressed in endometrial cancer (EC) cell lines, albeit at various levels (Fig. 1a). This led us to investigate PIR2 expression pattern in primary tissues. Analysis of normal ($n = 8$) and malignant ($n = 14$) endometrial tissue samples

revealed that PIR2 protein is present exclusively in tumour samples but not in normal endometrium (Fig. 1b). In EC tumour samples, PIR2 is predominantly localised to cytoplasm, as described previously²⁹ (Fig. 1c). These data suggested that PIR2 is a potential EC biomarker and prompted us to investigate the functional significance of PIR2 expression in EC.

To assess whether PIR2 expression confers a selective growth or survival advantage to cancer cells, we silenced its expression in KLE cells, which express high levels of PIR2 protein and performed proliferation assays. Loss of PIR2 had a cytostatic effect, which was associated with increased G1 population (Fig. 1d and Supplementary Figure S1A). PIR2-depletion in Hec1A and Ishikawa cells, which express low levels of PIR2 did not have a detectable effect on proliferation (Supplementary Figure S1B). Unlike KLE cells, both Hec1A and Ishikawa cells are ER positive and oestrogen acts as the principal driver for proliferation^{31,32}. As such, we hypothesised that the function of PIR2 might become evident in the absence of oestrogenic stimuli. To this end, we starved Ishikawa cells for oestrogen in phenol-red free medium supplemented with charcoal-stripped FBS (withdrawal medium: WM), for 3 days. Surprisingly, lack of oestrogen signalling did not have an impact on Ishikawa cell proliferation, but led to a striking increase in PIR2 levels (Supplementary Figure S1C and Fig. 1e), suggesting that upregulation of PIR2 may function to sustain proliferation in the absence of oestrogen. To test this, we inhibited PIR2 upregulation -in response to oestrogen withdrawal- by RNA interference and assessed cell proliferation (Supplementary Figure S1D). While scrambled transfected oestrogen-starved cells that express high levels of PIR2 proliferated efficiently in the absence of hormone-stimuli, cells that were deprived of PIR2 failed to do so (Fig. 1f). These results demonstrate that in the absence of oestrogenic growth stimuli, PIR2 promotes EC cell proliferation and suggest that inhibition of its expression may potentially have therapeutic implications.

PIR2 expression is regulated predominantly at post-translational level in tumour cells

To investigate how PIR2 can potentially be targeted, we sought to understand the molecular mechanisms that regulate PIR2 expression in EC cells. Here we first assessed potential contribution of transcriptional regulation, by analysing PIR2 transcript levels in EC cell lines, normal endometrium and EC tumours. Although PIR2 protein was hardly detectable in Hec1A and Ishikawa cells, at transcript level, these cell lines expressed relatively higher levels of PIR2 compared to KLE cells, suggesting that, in EC cell lines, PIR2 expression is not regulated transcriptionally (Fig. 2a, Supplementary Figure S2A). Furthermore, starvation of Ishikawa cells for




oestrogen did not alter PIR2 mRNA level, although its protein level was increased significantly (Fig. 1e, Fig. 2b, Supplementary Figure S2B). In normal endometrium, PIR2 transcript was readily detectable, albeit this was lower than tumour samples (Fig. 2c, d, Supplementary Figure S2C-D). Analysis of the TCGA-Uterine Corpus Endometrial Carcinoma RNA-seq data provided further support to our findings, showing that PIR2 is present at mRNA level in normal endometrium, although at lower quantities compared to tumour samples (Fig. 2e). These data suggest that both transcriptional and post-translational mechanisms conspire to the upregulation of PIR2 expression during malignant transformation, but in tumour cells post-translational regulation plays a major role.

Modulation of PIR2 protein levels in response to oestrogen withdrawal in Ishikawa cells suggested that we could use this cell line as a model to investigate how PIR2 expression is regulated. To better understand the mode of

PIR2 regulation in these cells, we assessed PIR2 protein levels 1-, 5- 60-min after oestrogen withdrawal and compared it to PIR2 levels in cells in GM or in WM for 24 h (Fig. 2f). PIR2 protein levels started to increase within minutes following oestrogen withdrawal, suggesting potential involvement of a kinase-signalling pathway regulating PIR2 protein abundance in EC cells.

PIR2 is phosphorylated downstream of GSK3 β

To assess whether PIR2 expression is regulated downstream of a kinase signalling pathway, we first performed an in silico analysis to investigate the presence of potential phosphorylation sites. By using NetPhos 2.0 (<http://www.cbs.dtu.dk/services/NetPhos/>), we identified 3 potential serine phosphorylation sites (S165, S250 and S301) and 3 potential threonine phosphorylation sites (T44, T119 and T128) (Fig. 3a). To validate these findings, we immunoprecipitated overexpressed-PIR2 from HEK293 cells and analysed the immune complexes by mass spectrometry





(MS). MS analysis revealed that PIR2 is phosphorylated at three serine residues: S38, S250 and S301. We then tested the impact of phosphorylation at these serine residues on PIR2 protein stability by generating phospho-mimetic PIR2 mutants and comparing the half-life of these mutants to wild-type PIR2. As shown in Fig. 3b and Supplementary Figure S3, only the phospho-mimetic mutation at S301 enhanced the stability of PIR2, while the S38D and S250D mutants had little, if any, effect on the stability of the protein. These findings demonstrate that phosphorylation of PIR2 at S301 is critical for its stability and prompted us to identify the kinase that is responsible for PIR2 phosphorylation and hence, stability.

By screening the PKIS (Published Kinase Inhibitory Set) from GlaxoSmithKline we identified that the inhibition of GSK3 β leads to a significant loss of PIR2 protein, suggesting that GSK3 β acts as a regulator of PIR2 stability (Supplementary table S1). Depletion of GSK3 β in KLE cells resulted in loss of PIR2 protein and depletion of GSK3 β in Ishikawa cells inhibited the accumulation of PIR2 protein in response to oestrogen withdrawal (Fig. 3c). In oestrogen-starved cells, accumulation of PIR2 protein paralleled loss of S9-phosphorylated inactive

isoform of GSK3 β (Fig. 2e and Fig. 3d). These data demonstrate that PIR2 protein stability is associated, predominantly, with the modulation of GSK3 β activity.

Phosphorylation of PIR2 protects it from proteasomal degradation

Proteasomal degradation is among the major pathways that regulate protein turnover in cells^{33,34}. As PIR2 expression is regulated predominantly at protein level in EC, we asked whether inhibition of proteasome activity would affect PIR2 levels. As a proof of principle experiment, we treated Ishikawa cells in GM with the proteasome inhibitor MG132 and analysed the changes in PIR2 protein levels (Fig. 4a). Upon inhibition of proteasome activity, PIR2 levels increased, suggesting that in these cells PIR2 is constitutively degraded by the proteasome. To further assess the impact of GSK3 β on PIR2 stability, we analysed PIR2 protein levels in GSK3 β -depleted KLE cells and oestrogen-starved Ishikawa cells, in the presence or absence of the proteasome inhibitor MG132 (Fig. 4b). In both experimental settings, inhibition of proteasome restored PIR2 protein levels following GSK3 β -depletion, demonstrating that phosphorylation of PIR2 downstream




of GSK3 β protects it from proteasomal degradation (Fig. 4b).

To further confirm the role of GSK3 β in the inhibition of PIR2 degradation, we treated oestrogen-starved Ishikawa cells with GSK3 β inhibitors lithium chloride and AZD1080 (Fig. 4c). While both inhibitors induced loss of PIR2 protein, treatment of cells with MG132 restored PIR2 levels. Treatment of KLE cells with GSK3 β inhibitors also confirmed these findings (Supplementary Figure S4).

Inhibition of PIR2 expression by GSK3 β inhibitors impairs EC cell proliferation

To assess the impact of modulation of PIR2 stability by GSK3 β inhibitors on cell proliferation, we first treated KLE cells with LiCl and analysed cell growth dynamics for up to 5 days. As shown in Fig. 5a, LiCl impaired proliferation significantly, supporting previously published effects of GSK3 β inhibitors on EC cell proliferation²⁴. We also tested the effect of LiCl on oestrogen-starved Ishikawa cells (Fig. 5b). While untreated cells proliferated rapidly, LiCl treatment had a severe cytostatic effect on these cells. The effect of LiCl on cell proliferation was more prominent compared to PIR2 depletion, potentially



due to effect of lithium on multiple cellular signalling pathways. Nevertheless, our data suggest that expression of PIR2, downstream of GSK3 β , is an important mechanism that drives EC cell proliferation and inhibition of the GSK3 β -PIR2 signalling axis impairs proliferation in EC.

GSK3 β -PIR2 axis in endometrial tumours

After characterising the GSK3 β -PIR2 signalling axis in EC cell lines, we sought to investigate whether a similar axis was also present in tumour samples. Analysis of GSK3 β and S9-GSK3 β levels in our tumour panel demonstrated that GSK3 β is in active state in the majority of the tumours (Fig. 6a). These data show that in EC, GSK3 β is important for maintenance of tumorigenic phenotype and that there is a correlation between GSK3 β activity and PIR2 expression *in vivo* (Fig. 6a).

In normal endometrium and in breast cancer cell lines, GSK3 β is typically inactivated by the oestrogen receptor-AKT pathway^{21,35–37}. If GSK3 β were indeed critical for EC tumour maintenance, then it would be plausible to hypothesise that AKT-GSK3 β axis would be impaired in endometrial tumours, to maintain high levels of GSK3 β activity. To test this hypothesis, we analysed the tumour samples for the active form of AKT. It has been reported that >80% of EC tumours harbour mutations that target and activate AKT^{17–20} and in parallel with this, we detected S473-AKT in 91% of the samples (Fig. 6a). However, we did not detect a correlation between

activation of AKT and inactivation of GSK3 β , suggesting that in EC, AKT-GSK3 β signalling axis is not functional.

To provide further support to this hypothesis, we assessed the AKT-GSK3 β axis by comparing S473-AKT levels in the Ishikawa cells in GM and WM. As reported previously, these cells express high levels of inactive GSK3 β and active AKT, under normal growth conditions (GM)³⁸. However, in response to oestrogen withdrawal, although S9-GSK3 β levels were reduced dramatically, we could not detect a significant change in S473-AKT levels (Fig. 6b). These data support our finding in tumour samples demonstrating that GSK3 β is not regulated downstream of AKT.

Discussion

Although most women with EC are cured by surgery and radiotherapy, nearly 20% present with aggressive disease that has an extremely poor prognosis. Improving outcomes for these patients requires early diagnosis and effective targeted therapy, which in turn necessitates the identification of endometrial cancer biomarkers^{39,40}.

Several oncogenes and tumour suppressor genes have previously been identified as biomarkers in EC, including K-ras⁴¹, HER2⁴², PI3KCA⁴³, FGFR2⁴⁴, PTEN⁴⁵ and p53⁴⁶. While most of these serve as prognostic predictors, only a few stand out as potential therapeutic targets⁴⁷. Here we have shown, by using a panel of normal endometrial tissue, endometrial cancer samples and EC cell lines that PIR2 (i) is exclusively expressed in EC and not in normal endometrium (Fig. 1), (ii) is important for EC cell proliferation (Fig. 1), and (iii) can be targeted by using GSK3 β inhibitors (Figs. 3 and 4); substantiating PIR2 is a potential targetable biomarker for EC.

As stated by Hanahan and Weinberg, “*sustaining proliferative signalling is the most fundamental trait of cancer cells*”⁴⁸. We have previously shown that PIR2 is critical for the proliferation of keratinocytes and HNSCC cells²⁹ and here, we showed that PIR2 is also important for the proliferation in EC cells, especially in the absence of steroid hormone receptor mediated mitogenic signals (Fig. 1). Of note, PIR2 expression was detected in 14 out of 14 tumour samples (100%). Taken together, these findings suggest that PIR2 functions as an oncogene.

To assess the function of PIR2 in EC and to investigate the molecular mechanisms that regulate its cellular levels, we used two EC cell lines as model systems. Ishikawa cells, which express relatively lower levels of PIR2, are ER-positive and also express high levels of S473-AKT. Here, depletion of PIR2 expression did not cause a significant cytostatic effect, potentially due to the powerful effects of ER and AKT on cell proliferation. Indeed, when we inhibited ER signalling, we observed increased PIR2 expression, which was associated with proliferation. Here, the cells which failed to increase PIR2 expression, showed




Fig. 6 AKT-GSK3 β axis in EC. **a** Tumour samples used in Fig. 1 were used to analyse the expression and activity of GSK3 β and AKT in EC by western blotting. **b** S9-phosphorylation of GSK3 β in relation to AKT activity was assessed in Ishikawa cells in GM and WM. Tubulin was used to assess equal protein loading

signs of impaired proliferation (Fig. 1f). KLE cells, on the other hand, are ER-negative⁴⁹ and express low levels of S473-AKT³⁸, and as such are in need for alternative oncogenic signals. This may explain why this cell line expresses higher levels of PIR2 protein.

A thorough investigation revealed that although PIR2 transcript is ubiquitously expressed in the endometrium and in EC, its protein levels are tightly regulated downstream of GSK3 β , where un-phosphorylated PIR2 protein is degraded by the proteasome (Fig. 3, Fig. 4). In normal endometrium, GSK3 β activity changes throughout the menstrual cycle: up to 5-fold higher levels of inactive GSK3 β during secretory phase (low oestrogen, high progesterone), compared to the proliferative phase (high oestrogen, low progesterone)⁵⁰. EC typically targets postmenopausal women with excessive un-opposed oestrogen activity (high oestrogen, low progesterone), as such creates an environment very similar to the proliferative phase of the menstrual cycle, with high levels of active GSK3 β . This also supports our data on the lack of S9-GSK3 β in the tested tumour samples (Fig. 6).

GSK3 β serine/threonine kinase has been implicated in many diseases and disorders including metabolic, immune and neurological disorders, aging and cancer²⁶. Its role in cancer is complex and controversial. While it is over-expressed and drives proliferation in glioblastoma, pancreatic cancer, ovarian cancer, prostate cancer, multiple myeloma, acute lymphocytic leukaemia, acute myeloid leukaemia and chronic lymphocytic leukaemia, it functions as a tumour suppressor in breast cancer and medullablastoma^{26,51–54}. In endometrial cancer cell lines, GSK3 β inhibitors exhibit anti-proliferative effects^{24,25}. This effect was shown in both ER-positive and ER-negative EC cell lines. Our results, however, demonstrate that in ER-positive cells in the presence of oestrogen, GSK3 β is predominantly inactive, as evidenced by high levels of S9-GSK3 β isoform (Figs. 3d and 6b). This

inhibitory effect of oestrogen on GSK3 β has previously been shown in brain, in particular, in association with tau phosphorylation^{55,56}. Therefore, as GSK3 β in ER-positive EC cell lines is already inactive, one explanation for the cytostatic effect of GSK3 β inhibitors in ER-positive EC cell lines could be due to the off-target actions of the kinase inhibitors used in these studies.

In order to advance the outcomes of cancer treatments, it is of vital importance to develop molecularly targeted therapeutics. Although use of GSK3 β inhibitors, based on their *in vitro* and *in vivo* cytostatic effects, might sound like a promising approach to treat EC, their effect on normal endometrium should also be considered thoroughly. Our findings, however, show that PIR2 is not expressed in normal endometrium, suggesting that potential specific PIR2 inhibitors could be used for the treatment of EC, without the risk of harming the normal uterine. This cancer specific expression profile of PIR2 and its targetable nature presents an exciting opportunity to develop therapeutic agents to treat EC.

Materials and methods

Cell culture

All cell lines were grown as recommended by ATCC. For withdrawal experiments, Ishikawa cells were washed at least three times with PBS and were cultured in phenol red free DMEM containing 10% Charcoal Stripped FBS. Experiments in withdrawal medium (WM) were performed following growth of Ishikawa cells in WM for 4–5 days to erase ER activation memory.

Treatments and transfections

Lipofectamine-2000 or RNAiMAX (Invitrogen) was used for transfections as described previously⁵⁷. Pre-designed siRNA targeting PIR2, and GSK3 β were purchased from Ambion Ltd. MG132 was from Bio-Mol, LiCl was from Sigma and AZD1080 was from Selleckchem.

Plasmids and stability assay

Human PIR2 cloned in pcDNA3.1 without any tags was used for stability assays. QuikChange II Site-Directed Mutagenesis Kit was used to generate the phosphomimetic mutants as described previously⁵⁸. Stability assays were performed following transfection of H1299 cells with indicated plasmids. Briefly, 6 h after transfection, cells were split into 6 cm plates and 24 h later treated with 75 μ m CHX. Cells were collected at indicated time points and cell lysates were run on acrylamide gels. PIR2-antibody²⁷ reactive bands were quantified by using ImageJ software and normalised results were plotted on a chart.

Mass spectrometry and western blot analysis

For mass spectrometry, PIR2 was overexpressed in HEK293 cells and immunoprecipitated by using anti-PIR2 antibody. 24 h following transfection, cells were collected and lysed in triton buffer [50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1 mM EGTA (pH 8.0), 100 mM NaF (pH 8.0), 10% glycerol, 1 mM MgCl₂, 1 mM sodium orthovanadate, 1% (v/v) Triton X-100 and complete protease inhibitors (Roche)]. PIR2 protein was precipitated by incubating the cell lysates with the PIR2 antibody. Immunoprecipitates were run on an acrylamide gel and the bands were revealed by colloidal Coomassie stain. Following destaining, a fraction of PIR2 band was removed from gel and subjected to mass spectrometry following incubation with proteolytic enzymes. For western blot analysis, tissues were homogenised and cell pellets were sonicated in lysis buffer (25 mM Tris (pH.6.8), 7% glycerol, 0.8% SDS). Proteins were denatured, separated on SDS polyacrylamide gels, and then transferred to nitrocellulose membranes. The following antibodies were used at dilutions suggested by the supplier: PIR2 antibody was generated as described before²⁷. Actin (sc1616), tubulin (sc-8035), GAPDH (sc-32233), GSK3 α/β (sc-7291) were from Santa Cruz. S9-GSK3 β (#5558), AKT (#4691) and S473-AKT (#4060) antibodies were from Cell Signalling. Immunoreactive proteins were detected using an enhanced chemiluminescence system (Thermo Fisher Scientific Inc).

Polymerase chain reaction

RNA extraction and cDNA synthesis were done as described before⁵⁹. Equal amount of RNA was used in cDNA synthesis. Quantitative PCRs were performed with TaqMan Universal Master mix with MJ Research DNA Engine Opticon2 or with QuantStudio-3 Real-Time PCR system. All TaqMan assays were purchased from Applied Biosystems. For semi-quantitative PCR the quality of cDNA was tested by GAPDH amplification (GF: 5'-GGCTGAGAACGGGAAGCTTGTCAT-3' and GR: 5'-CAGCCTTCTCCATGGTGGTGAAGA-3'). PIR2 expression was analysed with the primers: FL-PIR2-F: 5'-ATGGGCTCAGCTGGTAGGC-3' and

FL-PIR2-R: 5'-GGTTGTGGATGGGTCGTGCT-3'. The amplified DNA fragments were analysed as described previously⁶⁰.

The Cancer Genome Atlas (TCGA) RNA-seq data analysis

RNA-seq data from normal ($n = 24$) and tumour ($n = 176$) samples were downloaded from the TCGA-Uterine Corpus Endometrial Carcinoma project. The normalised RSEM value of PIR2 was extracted and compared between the tumour cohort and normal cohort. Statistical significance was calculated by the Mann–Whitney–Wilcoxon test in R.

Proliferation assay

For proliferation assays, cells were seeded in triplicate/quadruplicate in 24-well plates and fixed in 50/50% acetone/methanol at indicated times. Following staining with DAPI, images were acquired by using UV filter. The stained nuclei were counted using ImageJ software.

Cell cycle and apoptosis assays

For cell cycle and apoptosis assays, cells were collected, washed in PBS and re-suspended in hypotonic fluorochrome solution, made by diluting 1 mg/ml stock PI solution 1:20 (Sigma, UK) in hypotonic buffer (0.1% (w/v) sodium citrate, 0.1% (v/v) Triton X-100). The suspension was analysed by using BD Accuri™ C6 flow cytometry (BD biosciences, UK).

Immunohistochemistry

All tissue samples were taken from the BRC BioBank (Biobank ethics ref.: ¹⁴/NW/1260, HTA licence number: 12552). Paraffin sections were deparaffinized and stained with anti-PIR2 by using the DAKO DAB + Substrate Chromogen System (DAKO-K3467).

Screening of PKIS

N-TERT cells were treated with 100 nM of each drug and collected 5 h later. PIR2 levels were then assessed by western blotting and compared to that of untreated cells.

Acknowledgements

This work was supported by the funds given to B.S.S. by the UoM. E.J.C. is supported by an NIHR Clinician Scientist fellowship (NIHR-CS-012-009).

Author details

¹University of Manchester, Faculty of Medical and Human Sciences, Division of Cancer Sciences, Manchester Cancer Research Centre, Wilmslow Road, Manchester M20 4QL, UK. ²University of Southampton, Faculty of Medicine, Academic Unit of Clinical and Experimental Sciences, Southampton SO16 6YD, UK. ³Medical Research Council, Toxicology Unit, Hodgkin Building, Leicester University, Lancaster Road, P.O. Box 138, Leicester LE1 9HN, UK. ⁴Biochemistry Laboratory, IDI-IRCCS, and Department of Experimental Medicine and Biochemical Sciences, University of Rome "Tor Vergata", 00133 Rome, Italy

Conflict of interest

The authors declare that they have no conflict of interest.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information accompanies this paper at <https://doi.org/10.1038/s41419-018-0521-1>.

Received: 8 January 2018 Revised: 18 March 2018 Accepted: 23 March 2018

Published online: 02 May 2018

References

- Llaurado, M. et al. Molecular bases of endometrial cancer: new roles for new actors in the diagnosis and the therapy of the disease. *Mol. Cell Endocrinol.* **358**, 244–255 (2012).
- Amant, F. et al. Endometrial cancer. *Lancet* **366**, 491–505 (2005).
- Morice, P., Leary, A., Creutzberg, C., Abu-Rustum, N. & Darai, E. Endometrial cancer. *Lancet* **387**, 1094–1108 (2016).
- Hockel, M. & Dornhofer, N. Treatment of early endometrial carcinoma: is less more? *Lancet* **373**, 97–99 (2009).
- Hill, E. K. & Dizon, D. S. Medical therapy of endometrial cancer: current status and promising novel treatments. *Drugs* **72**, 705–713 (2012).
- Setiawan, V. W. et al. Type I and II endometrial cancers: have they different risk factors? *J. Clin. Oncol.* **31**, 2607–2618 (2013).
- Shaw, E., Farris, M., McNeil, J. & Friedenreich, C. Obesity and endometrial cancer. *Recent Results Cancer Res* **208**, 107–136 (2016).
- Iyengar, N. M., Hudis, C. A. & Dannenberg, A. J. Obesity and cancer: local and systemic mechanisms. *Annu Rev. Med.* **66**, 297–309 (2015).
- Khandekar, M. J., Cohen, P. & Spiegelman, B. M. Molecular mechanisms of cancer development in obesity. *Nat. Rev. Cancer* **11**, 886–895 (2011).
- Talhok, A. & McAlpine, J. N. New classification of endometrial cancers: the development and potential applications of genomic-based classification in research and clinical care. *Gynecol. Oncol. Res. Pract.* **3**, 14 (2016).
- Tsikouras, P. et al. Endometrial cancer: molecular and therapeutic aspects. *Eur. J. Obstet. Gynecol. Reprod. Biol.* **169**, 1–9 (2013).
- Zhang, Y. et al. Prognostic role of hormone receptors in endometrial cancer: a systematic review and meta-analysis. *World J. Surg. Oncol.* **13**, 208 (2015).
- Bogliolo, S. et al. Effectiveness of aromatase inhibitors in the treatment of advanced endometrial adenocarcinoma. *Arch. Gynecol. Obstet.* **293**, 701–708 (2016).
- Chlebowski, R. T., Schottinger, J. E., Shi, J., Chung, J. & Haque, R. Aromatase inhibitors, tamoxifen, and endometrial cancer in breast cancer survivors. *Cancer* **121**, 2147–2155 (2015).
- Barkhem, T., Nilsson, S. & Gustafsson, J. A. Molecular mechanisms, physiological consequences and pharmacological implications of estrogen receptor action. *Am. J. Pharm.* **4**, 19–28 (2004).
- Liang, J. & Shang, Y. Estrogen and cancer. *Annu Rev. Physiol.* **75**, 225–240 (2013).
- Cross, D. A., Alessi, D. R., Cohen, P., Andjelkovich, M. & Hemmings, B. A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. *Nature* **378**, 785–789 (1995).
- Cheung, L. W. et al. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. *Cancer Discov.* **1**, 170–185 (2011).
- Kanamori, Y. et al. Correlation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma. *Clin. Cancer Res.* **7**, 892–895 (2001).
- Sun, H. et al. Mutational analysis of the PTEN gene in endometrial carcinoma and hyperplasia. *Am. J. Clin. Pathol.* **115**, 32–38 (2001).
- Chen, B., Pan, H., Zhu, L., Deng, Y. & Pollard, J. W. Progesterone inhibits the estrogen-induced phosphoinositide 3-kinase–AKT–GSK-3beta–cyclin D1–pRB pathway to block uterine epithelial cell proliferation. *Mol. Endocrinol.* **19**, 1978–1990 (2005).
- Polotsky, A. J., Zhu, L., Santoro, N. & Pollard, J. W. Lithium chloride treatment induces epithelial cell proliferation in xenografted human endometrium. *Hum. Reprod.* **24**, 1960–1967 (2009).
- Joffe, H. Reproductive biology and psychotropic treatments in premenopausal women with bipolar disorder. *J. Clin. Psychiatry* **68**(Suppl 9), 10–15 (2007).
- Yin, Y. et al. Glycogen synthase kinase 3beta inhibition as a therapeutic approach in the treatment of endometrial cancer. *Int. J. Mol. Sci.* **14**, 16617–16637 (2013).
- Chen, S., Sun, K. X., Liu, B. L., Zong, Z. H. & Zhao, Y. The role of glycogen synthase kinase-3beta (GSK-3beta) in endometrial carcinoma: A carcinogenesis, progression, prognosis, and target therapy marker. *Oncotarget* **7**, 27538–27551 (2016).
- McCubrey, J. A. et al. GSK-3 as potential target for therapeutic intervention in cancer. *Oncotarget* **5**, 2881–2911 (2014).
- Sayan, B. S. et al. Differential control of TAp73 and DeltaNp73 protein stability by the ring finger ubiquitin ligase PIR2. *Proc. Natl Acad. Sci. USA* **107**, 12877–12882 (2010).
- Taebunpakul, P. et al. Apoptin induces apoptosis by changing the equilibrium between the stability of TAp73 and DeltaNp73 isoforms through ubiquitin ligase PIR2. *Apoptosis* **17**, 762–776 (2012).
- Conforti, F. et al. PIR2/Rnf144B regulates epithelial homeostasis by mediating degradation of p21WAF1 and p63. *Oncogene* **32**, 4758–4765 (2013).
- Ma, X. et al. Long non-coding RNA LOC554202 modulates chordoma cell proliferation and invasion by recruiting EZH2 and regulating miR-31 expression. *Cell Prolif.* **50**, 1–11 (2017).
- Joshi, A. et al. Endometrial tumorigenesis in Pten(+/-) mice is independent of coexistence of estrogen and estrogen receptor alpha. *Am. J. Pathol.* **180**, 2536–2547 (2012).
- Saito, T., Tanaka, R., Wataba, K., Kudo, R. & Yamasaki, H. Overexpression of estrogen receptor-alpha gene suppresses gap junctional intercellular communication in endometrial carcinoma cells. *Oncogene* **23**, 1109–1116 (2004).
- Collins, G. A. & Goldberg, A. L. The logic of the 26S proteasome. *Cell* **169**, 792–806 (2017).
- Bernassola, F., Ciechanover, A. & Melino, G. The ubiquitin proteasome system and its involvement in cell death pathways. *Cell Death Differ.* **17**, 1–3 (2010).
- Medunjanin, S. et al. Glycogen synthase kinase-3 interacts with and phosphorylates estrogen receptor alpha and is involved in the regulation of receptor activity. *J. Biol. Chem.* **280**, 33006–33014 (2005).
- Zhu, L. & Pollard, J. W. Estradiol-17beta regulates mouse uterine epithelial cell proliferation through insulin-like growth factor 1 signaling. *Proc. Natl Acad. Sci. USA* **104**, 15847–15851 (2007).
- Zhang, H., McElrath, T., Tong, W. & Pollard, J. W. The molecular basis of tamoxifen induction of mouse uterine epithelial cell proliferation. *J. Endocrinol.* **184**, 129–140 (2005).
- Jin, X. et al. Inhibition of AKT survival pathway by a small molecule inhibitor in human endometrial cancer cells. *Br. J. Cancer* **91**, 1808–1812 (2004).
- Dong, P. et al. Emerging therapeutic biomarkers in endometrial cancer. *Biomed. Res. Int.* **2013**, 130362 (2013).
- Thanappapas, D., Cheewakriangkrai, C., Likittanasombut, P., Thanappapas, K. & Mutch, D. G. Targeted endometrial cancer therapy as a future prospect. *Women's Health* **9**, 189–199 (2013).
- Caduff, R. F., Johnston, C. M. & Frank, T. S. Mutations of the Ki-ras oncogene in carcinoma of the endometrium. *Am. J. Pathol.* **146**, 182–188 (1995).
- Berchuck, A. et al. Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. *Am. J. Obstet. Gynecol.* **164**, 15–21 (1991).
- Oda, K., Stokoe, D., Taketani, Y. & McCormick, F. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. *Cancer Res.* **65**, 10669–10673 (2005).
- Dutt, A. et al. Drug-sensitive FGFR2 mutations in endometrial carcinoma. *Proc. Natl Acad. Sci. USA* **105**, 8713–8717 (2008).
- Tashiro, H. et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. *Cancer Res.* **57**, 3935–3940 (1997).
- Risinger, J. I. et al. p53 gene mutations in human endometrial carcinoma. *Mol. Carcinog.* **5**, 250–253 (1992).
- Banno, K. et al. Biomarkers in endometrial cancer: Possible clinical applications (review). *Oncol. Lett.* **3**, 1175–1180 (2012).
- Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. *Cell* **144**, 646–674 (2011).
- Hou, X., Zhao, M., Wang, T. & Zhang, G. Upregulation of estrogen receptor mediates migration, invasion and proliferation of endometrial carcinoma cells by regulating the PI3K/AKT/mTOR pathway. *Oncol. Rep.* **31**, 1175–1182 (2014).
- Salameh, W., Helliwell, J. P., Han, G., McPhaul, L. & Khorram, O. Expression of endometrial glycogen synthase kinase-3beta protein throughout the menstrual cycle and its regulation by progesterone. *Mol. Hum. Reprod.* **12**, 543–549 (2006).

51. Ougolkov, A. V., Fernandez-Zapico, M. E., Savoy, D. N., Urrutia, R. A. & Billadeau, D. D. Glycogen synthase kinase-3beta participates in nuclear factor kappaB-mediated gene transcription and cell survival in pancreatic cancer cells. *Cancer Res.* **65**, 2076–2081 (2005).
52. Dal Col, J. & Dolcetti, R. GSK-3beta inhibition: at the crossroad between Akt and mTOR constitutive activation to enhance cyclin D1 protein stability in mantle cell lymphoma. *Cell Cycle* **7**, 2813–2816 (2008).
53. Martinez, A. Preclinical efficacy on GSK-3 inhibitors: towards a future generation of powerful drugs. *Med Res. Rev.* **28**, 773–796 (2008).
54. Patel, S. & Woodgett, J. Glycogen synthase kinase-3 and cancer: good cop, bad cop? *Cancer Cell* **14**, 351–353 (2008).
55. Cardona-Gomez, P., Perez, M., Avila, J., Garcia-Segura, L. M. & Wandosell, F. Estradiol inhibits GSK3 and regulates interaction of estrogen receptors, GSK3, and beta-catenin in the hippocampus. *Mol. Cell Neurosci.* **25**, 363–373 (2004).
56. Goodenough, S., Conrad, S., Skutella, T. & Behl, C. Inactivation of glycogen synthase kinase-3beta protects against kainic acid-induced neurotoxicity in vivo. *Brain Res.* **1026**, 116–125 (2004).
57. Sayan, B. S. et al. Cleavage of the transactivation-inhibitory domain of p63 by caspases enhances apoptosis. *Proc. Natl Acad. Sci. USA* **104**, 10871–10876 (2007).
58. Sayan, B. S., Sayan, A. E., Knight, R. A., Melino, G. & Cohen, G. M. p53 is cleaved by caspases generating fragments localizing to mitochondria. *J. Biol. Chem.* **281**, 13566–13573 (2006).
59. Tucci, P. et al. Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer. *Proc. Natl Acad. Sci. USA* **109**, 15312–15317 (2012).
60. Eldakhkhny, S., Zhou, Q., Crosbie, E. J. & Sayan, B. S. Human papillomavirus E7 induces p63 expression to modulate DNA damage response. *Cell Death Dis.* **9**, 127 (2018).